Quantum
Martin Beaulieu, Ph.D.
Dr. Martin Beaulieu is a biochemist with expertise in the development of molecular applications and diagnostic assay development. In the past 16 years, Dr. Beaulieu led research & development activities in academic and bio-pharmaceutical organizations. He holds a Bachelor of Science degree in Biochemistry (1993) from Laval University and a Ph.D. in Physiology-Endocrinology from the Faculty of Medicine (1998) at Laval University.
Dr. Beaulieu’s Ph.D thesis focused on steroid hormones and drug metabolizing enzymes called UGTs. His work contributed to the demonstration of the role of the UGT enzymes in controlling steroid hormones homeostasis and cellular hormonal response in cancer cells. He authored 20 peer-reviewed scientific publications. During a post-doctoral fellowship, Dr. Beaulieu developed a novel mutation detection assay at the Beckman Research Institute at the City of Hope National Medical Center in Duarte, CA. At Sequenom, Inc., formerly a genetic systems company in San Diego, he led the development and optimization of molecular applications based on MALDI-TOF Mass Spectrometry and launched the iPLEX™ genotyping system. At DiagnoCure, Inc. Dr. Beaulieu led cancer biomarker discovery studies and the development of a high-value molecular diagnostic test for staging colorectal cancer (Previstage™). Dr. Beaulieu supported the management of diagnostic assay development at Abbott Point of Care and recently led the Regulus microMarkers™ R&D division at Regulus Therapeutics, Inc.
In 2016, Dr. Beaulieu traded his biotech legacy for the reins of Quantum Brewing, a craft nanobrewery in the heart of San Diego. As CEO and Head Brewer at Quantum Brewing, Dr. Beaulieu’s combines his biochemistry skills with his life-long passion of making craft beer that attains the perfect balance of bitterness, flavor and aroma.